- Sequana Therapeutics, of La Jolla, Calif., is teaming up with theUniversity of Bristol, in England, to identify genes associated withulcerative colitis, also known as inflammatory bowel disease.- Ariad Pharmaceuticals Inc., Cambridge, Mass., was awarded a$500,000 Small Business Innovation Research grant to supportdevelopment of a small-molecule drug to treat osteoporosis.- MedClone Inc., Los Angeles, netted about $500,000 from theexercisement of 290,000 warrants to purchase MedClone preferredstock at $1.72 per share. The Global Health Sciences Fund managedby Invesco Trust Co. exercised the warrants, which were obtained aspart of an October 1993 private financing in which funds managed byInvesco invested $2 million in MedClone.- Viragen Inc., Hialeah, Fla., said the Multiple Sclerosis FoundationInc. has established a special fund to give financial assistance for MSpatients participating in Viragen studies of its natural alpha interferonproduct, Alpha Leukoferon.- Anthra Pharmaceuticals Inc., Princeton, N.J., completed Phase Itesting of intraperitoneal AD 32, a lipophilic anthracycline analog, asa chemotherapeutic drug in patients with refractory ovarian cancer.AD 32 also was granted orphan drug status as a chemotherapeuticdrug for intravesical treatment of specific types of superficial bladdercancer.- Dura Pharmaceuticals Inc., San Diego, said a pilot study of itsDryhaler, a dry powder pulmonary drug delivery system, demonstratedeffectiveness in delivering a drug to the human lungs.- Neurogen Corp., Branford, Conn., said a group of investors led byAllen & Co. and Schroder Ventures has purchased David Blech'sequity position in the company. Blech owned or controlled about 13percent of Neurogen common stock.- Univax Biologics Inc., Rockville, Md., executed a commitment letterfor a $45 million project financing agreement with financing companyThe BioPlex Group Ltd. The agreement will lead to construction of anew complex for Univax that will include pilot vaccine and polyclonalantibody production plants and laboratories.- The Immune Response Corp., Carlsbad, Calif., will relocate theoperations of its wholly owned subsidiary, TargeTech Inc., fromMeriden, Conn., to Carlsbad. It is expected to be completed by the endof the year.- NeoRx. Corp., Seattle, reported data from the first stage of a Phase Itrial that showed the tumor-to-blood ratios for Acividin improvedeight-fold over conventional immunotherapy.- Somatix Therapy Corp., Alameda, Calif., has vaccinated the firstpatient in a Phase I gene therapy trial of its GVAX cancer vaccine inpatients with advanced melanoma.
(c) 1997 American Health Consultants. All rights reserved.